LifeSci Capital Initiates Coverage of Gemphire Therapeutics

Lead Product Gemcabene is Being Developed for Several Dyslipidemia Disorders;
Report Available Here: http://www.lifescicapital.com/equity-research/gemphire/

NEW YORK, NY / ACCESSWIRE / January 4, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Gemphire Therapeutics (NasdaqGM: GEMP), a clinical-stage biotechnology company focused on the development compounds for the treatment of diseases that affect cardiovascular and metabolic systems. The Company’s lead drug candidate is gemcabene, which is currently being developed for the treatment of various forms of dyslipidemia.

Gemphire has ongoing clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, and also plans to initiate a study in severe hypertriglyceridemia (SHTG) in the near future. Primary endpoints for the dyslipidemia trials all focus on lipid lowering, and topline results from these studies are expected in 2017. Due to gemcabene’s mechanism of action, this asset also has potential to treat liver indications such as NASH, which Gemphire may pursue in the future.

Gemcabene is an oral, first-in-class, once-daily tablet that functions through two mechanisms of action: reduced hepatic production of cholesterol and triglycerides, and enhanced clearance of very low-density lipoprotein (VLDL). All of Gemphire’s ongoing trials utilize one of two biomarkers as their primary endpoint, plasma levels of LDL-C or triglycerides. Gemcabene has previously demonstrated its ability to lower each of these lipids in various Phase II clinical trials. Due to the large number of individuals affected by the various dyslipidemia disorders, there is a large and growing potential market opportunity for gemcabene. The largest constituents of the addressable market are ASCVD and SHTG, which affect a total of 6.8 and 4.2 million patients in the US, respectively. Gemphire is also assessing gemcabene in HoFH and HeFH, which affect a combined 640,000 patients.

In a 35 page Initiation Report, LifeSci Capital describes the Company’s treatment for dyslipidemia disorders, how the product is differentiated from other therapies, and the large market opportunity for ASCVD and SHTG, as well as other indications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Gemphire as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 452183